These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35902325)

  • 1. Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles.
    Hsu R; Herrmann A; Gaur K; Xia B; Nieva JJ
    Clin Lung Cancer; 2022 Nov; 23(7):e443-e452. PubMed ID: 35902325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".
    Arrieta O; Ramírez-Tirado LA; Báez-Saldaña R; Peña-Curiel O; Soca-Chafre G; Macedo-Perez EO
    Lung Cancer; 2015 Nov; 90(2):161-6. PubMed ID: 26358312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?
    Bauml J; Mick R; Zhang Y; Watt CD; Vachani A; Aggarwal C; Evans T; Langer C
    Lung Cancer; 2013 Sep; 81(3):347-353. PubMed ID: 23806795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).
    Arrieta O; Cardona AF; Martín C; Más-López L; Corrales-Rodríguez L; Bramuglia G; Castillo-Fernandez O; Meyerson M; Amieva-Rivera E; Campos-Parra AD; Carranza H; Gómez de la Torre JC; Powazniak Y; Aldaco-Sarvide F; Vargas C; Trigo M; Magallanes-Maciel M; Otero J; Sánchez-Reyes R; Cuello M
    J Thorac Oncol; 2015 May; 10(5):838-843. PubMed ID: 25634006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer.
    Saber A; van der Wekken AJ; Kerner GS; van den Berge M; Timens W; Schuuring E; ter Elst A; van den Berg A; Hiltermann TJ; Groen HJ
    PLoS One; 2016; 11(3):e0152317. PubMed ID: 27008036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
    Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
    J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.
    Choi YL; Sun JM; Cho J; Rampal S; Han J; Parasuraman B; Guallar E; Lee G; Lee J; Shim YM
    PLoS One; 2013; 8(2):e56011. PubMed ID: 23468851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
    Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
    Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
    Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutations in US Hispanic versus non-Hispanic white patients with lung adenocarcinoma.
    Zhang W; McQuitty EB; Olsen R; Fan H; Hendrickson H; Tio FO; Newton K; Cagle PT; Jagirdar J
    Arch Pathol Lab Med; 2014 Apr; 138(4):543-5. PubMed ID: 23937608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping non-small cell lung cancer (NSCLC) in Latin America.
    Arrieta O; Cardona AF; Federico Bramuglia G; Gallo A; Campos-Parra AD; Serrano S; Castro M; Avilés A; Amorin E; Kirchuk R; Cuello M; Borbolla J; Riemersma O; Becerra H; Rosell R;
    J Thorac Oncol; 2011 Nov; 6(11):1955-9. PubMed ID: 22005474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
    Rulli E; Marabese M; Torri V; Farina G; Veronese S; Bettini A; Longo F; Moscetti L; Ganzinelli M; Lauricella C; Copreni E; Labianca R; Martelli O; Marsoni S; Broggini M; Garassino MC;
    Ann Oncol; 2015 Oct; 26(10):2079-84. PubMed ID: 26209642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race-Associated Genomic Correlates of Therapeutic Response in African American Patients With Non-Small-Cell Lung Cancer.
    Li P; Kane K; Wolf FM; Berry AB; Gadgeel S; Pilling A
    JCO Precis Oncol; 2023 Aug; 7():e2300155. PubMed ID: 37625101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
    Li Y; Li Y; Yang T; Wei S; Wang J; Wang M; Wang Y; Zhou Q; Liu H; Chen J
    PLoS One; 2013; 8(1):e52093. PubMed ID: 23341890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.